Bikini moguls Natasha Oakley and Devin Brugman made the most of the Caribbean sun this week. The Monday Swimwear founders were spotted catching some rays and showing off their beach-ready bodies ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The newsletter was supposed to be on ...

Eric Green, the longtime director of the National Human Genome Research Institute, has abruptly left his role. Sutro Biopharma announced that Bill Newell and the company’s board of directors have ...

Vivo V50 Lite 4G sports a 6.77-inch full-HD+ 2.5D pOLED display The handset is powered by a Snapdragon 685 SoC The Vivo V50 Lite 4G ships with Android 15-based FuntouchOS 15 ...

Sutro Biopharma is cutting 65 jobs across two Bay Area locations. The layoffs, which are permanent according to state filings, will see three people lose their jobs at Sutro’s South San ...

H.C. Wainwright downgraded Sutro Biopharma (STRO) to Neutral from Buy with a price target of $2, down from $12, after the company announced a strategic realignment focused on advancing its next ...

The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater – SOUTH SAN FRANCISCO, CA, USA I March ...

Revenue: US$62.0m (down 60% from FY 2023). Net loss: US$227.5m (loss widened by 113% from FY 2023). US$2.96 loss per share (further deteriorated from US$1.78 loss in FY 2023). Revenue exceeded ...

SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...

On Friday, Oppenheimer analysts downgraded Sutro Biopharma (NASDAQ:STRO) stock from Outperform to Perform, following the company’s announcement of its fourth-quarter 2024 financial results and ...

Sutro Biopharma (NASDAQ:STRO) fell ~14% in the premarket on Friday after the company announced its decision to deprioritize its studies into the antibody-drug conjugate luveltamab tazevibulin as ...

Sutro Bio­phar­ma is re­duc­ing its head­count by 50%, ap­point­ing a new CEO, shut­ting down its on­ly fac­to­ry, and shift­ing away from its lead can­di­date. … ...